| |FEBRUARY 20269SANOFI'S VENGLUSTAT SHOWS BREAKTHROUGH RESULTS IN GD3 TRIALCIPLA LAUNCHES 'WIN OVER WEIGHT' CAMPAIGN ON OBESITY CARESanofi today reported positive phase 3 LEAP2MONO results showing venglustat delivering meaningful neurological benefits for adults and children with type 3 Gaucher disease (GD3), a rare disorder with no approved treatments for brain-related symptoms. The LEAP2MONO results from Sanofi highlight progress for a long-neglected patient population.LEAP2MONO enrolled adult and pediatric patients with neurological manifestations of GD3. Venglustat, a glucosylceramide synthase inhibitor, reduces toxic sugar-fat buildup and crosses the blood-brain barrier."These findings underscore Sanofi's commitment to rare disease research and the promise we aim to deliver for people living with these conditions," said Houman Ashrafian, Executive Vice President and Head of Research and Development at Sanofi."What excites us most is the potential to address critical unmet medical needs. A daily pill could make a serious difference for Gaucher patients facing neurological challenges. Most importantly, none of this would be possible without the courage of the patients and families who participate in our studies, and for that we owe them a debt of gratitude," he added.By week 52, the venglustat patients experienced statistically significant neurological improvement scores based on modified SARA and RBANS scores compared to enzyme replacement therapy. Liver and spleen volume and hemoglobin were similar in terms of non-neurological measures.The drug was generally well tolerated, with no new safety signals. Common adverse events included headache, nausea, spleen enlargement, and diarrhea. Venglustat is also being studied in Fabry disease, where the phase 3 PERIDOT trial missed its primary endpoint and CARAT is assessing cardiac outcomes. Sanofi plans global regulatory filings for GD3. POCipla Limited has announced their "Win Over Weight" campaign on a national scale to create a new impression of obesity in India. "Win Over Weight" will move the conversation away from weight-based stigma to a conversation that focuses on being healthy and thriving due to tangible benefits (i.e., daily living skills, such as mobility, self-esteem, and quality of life), by re-positioning the idea of seeing a doctor as an empowering decision, rather than the last option."Win Over Weight" is a comprehensive program designed throughout the campaign whereby the message will promote an empathetic, scientific-based approach to understanding obesity, explain/inform regarding ongoing efforts to manage health conditions for many years, provide real-life examples of success from medical & lifestyle programs, and make the solution relatable and accessible through easy-to-understand education about how to care for obesity.According to a Cipla spokesperson, "Obesity is a multifaceted, progressive disease with serious health implications; however, there are many misconceptions regarding this condition." The spokesperson continued to say that the goal of the campaign will be to change the management of the disease from science to the basis of stigma and make the act of going to see a medical professional earlier than the act of responsibility and empowering an individual's health journey.According to Rohit Malkani, Chief Creative Officer of Saatchi & Saatchi India, "This campaign provides a story based on the personal experience of individuals who are successfully managing their weight through positive messages and real experiences, creating a story about how to transform the way India talks about obesity through inspiring and educating the public". PO
< Page 8 | Page 10 >